Skip to main content

Compare Stocks

Date Range: 

 PfizerNovartisAbbott LaboratoriesMerck & Co., Inc.AbbVie
SymbolNYSE:PFENYSE:NVSNYSE:ABTNYSE:MRKNYSE:ABBV
Price Information
Current Price$40.24$88.35$117.54$78.86$116.81
52 Week RangeHoldHoldBuyBuyBuy
MarketRank™
Overall Score2.12.02.22.22.7
Analysis Score2.13.21.42.41.4
Community Score2.92.32.82.52.9
Dividend Score2.52.53.32.55.0
Ownership Score1.70.01.71.71.7
Earnings & Valuation Score1.31.91.91.92.5
Analyst Ratings
Consensus RecommendationHoldHoldBuyBuyBuy
Consensus Price Target$39.94$108.50$125.81$97.50$117.13
% Upside from Price Target-0.75% downside22.81% upside7.04% upside23.64% upside0.27% upside
Trade Information
Market Cap$221.38 billion$200.42 billion$206.73 billion$197.50 billion$203.04 billion
Beta0.70.590.830.430.84
Average Volume32,432,7911,976,2145,208,74911,859,3417,192,412
Sales & Book Value
Annual Revenue$51.75 billion$47.50 billion$31.90 billion$46.84 billion$33.27 billion
Price / Sales4.344.266.554.266.20
Cashflow$4.49 per share$7.47 per share$5.27 per share$6.41 per share$10.92 per share
Price / Cash8.9711.8222.3112.3110.70
Book Value$11.46 per share$24.53 per share$17.70 per share$10.21 per share($5.53) per share
Price / Book3.513.606.647.72-21.12
Profitability
Net Income$16.27 billion$11.73 billion$3.69 billion$9.84 billion$7.88 billion
EPS$2.95$5.24$3.24$5.19$8.94
Trailing P/E Ratio25.9628.5962.1917.4524.70
Forward P/E Ratio13.1513.5526.8412.999.60
P/E Growth2.791.762.061.891.54
Net Margins17.85%14.71%10.50%24.33%18.16%
Return on Equity (ROE)24.88%24.39%18.19%53.83%439.24%
Return on Assets (ROA)9.32%10.59%8.29%16.83%13.22%
Dividend
Annual Payout$1.56$2.08$1.80$2.60$5.20
Dividend Yield3.88%2.35%1.53%3.30%4.45%
Three-Year Dividend Growth-10.94%13.60%35.85%31.22%84.37%
Payout Ratio52.88%39.69%55.56%50.10%58.17%
Years of Consecutive Dividend Growth1 Years1 Years49 Years1 Years49 Years
Debt
Debt-to-Equity Ratio0.76%0.49%0.58%0.90%5.38%
Current Ratio1.40%0.91%1.70%1.30%0.95%
Quick Ratio1.13%0.69%1.19%1.00%0.81%
Ownership Information
Institutional Ownership Percentage67.36%9.86%72.58%72.86%67.49%
Insider Ownership Percentage0.08%0.01%1.70%0.28%0.09%
Miscellaneous
Employees78,500105,794109,00073,00047,000
Shares Outstanding5.58 billion2.29 billion1.78 billion2.53 billion1.77 billion
Next Earnings Date7/27/2021 (Estimated)7/20/2021 (Estimated)7/15/2021 (Estimated)7/30/2021 (Estimated)7/30/2021 (Estimated)
OptionableOptionableOptionableOptionableOptionableOptionable
SourceHeadline
Alvogen Chairman Interview on Suing AbbVie on Humira Biosimilar - Business InsiderAlvogen Chairman Interview on Suing AbbVie on Humira Biosimilar - Business Insider
businessinsider.com - May 13 at 11:09 AM
Inventiva reports first quarter 2021 financial information and updates on the collaboration with AbbVie in auto - GlobeNewswireInventiva reports first quarter 2021 financial information and updates on the collaboration with AbbVie in auto - GlobeNewswire
globenewswire.com - May 12 at 5:57 PM
AbbVie Inc. (NYSE: ABBV) Topped Its Sales Forecast For Botox And Other Cosmetic Products In Q1 - Journal TranscriptAbbVie Inc. (NYSE: ABBV) Topped Its Sales Forecast For Botox And Other Cosmetic Products In Q1 - Journal Transcript
journaltranscript.com - May 12 at 12:55 PM
AbbVie to Present at the RBC Capital Markets Global Healthcare Conference - Yahoo FinanceAbbVie to Present at the RBC Capital Markets Global Healthcare Conference - Yahoo Finance
finance.yahoo.com - May 12 at 12:55 PM
Alvotech takes AbbVie to court over alleged patent minefield surrounding megablockbuster Humira - Endpoints NewsAlvotech takes AbbVie to court over alleged patent 'minefield' surrounding megablockbuster Humira - Endpoints News
endpts.com - May 12 at 12:55 PM
AbbVie to Present at the RBC Capital Markets Global Healthcare ConferenceAbbVie to Present at the RBC Capital Markets Global Healthcare Conference
finance.yahoo.com - May 12 at 12:55 PM
Alvotech files lawsuit challenging AbbVies Humira patent thicket - - pharmaphorumAlvotech files lawsuit challenging AbbVie's Humira patent thicket - - pharmaphorum
pharmaphorum.com - May 12 at 7:54 AM
The Zacks Analyst Blog Highlights: Exxon Mobil, AbbVie, Citigroup, Google and MicronThe Zacks Analyst Blog Highlights: Exxon Mobil, AbbVie, Citigroup, Google and Micron
finance.yahoo.com - May 12 at 7:54 AM
Abbvies Patents on Humira Challenged by Alvotech - Bloomberg LawAbbvie's Patents on Humira Challenged by Alvotech - Bloomberg Law
news.bloomberglaw.com - May 11 at 8:43 PM
AbbVie Enters Growing Market for Tattoo Removal, Cellulite Treatment - Yahoo FinanceAbbVie Enters Growing Market for Tattoo Removal, Cellulite Treatment - Yahoo Finance
finance.yahoo.com - May 11 at 8:43 PM
Alvotech, not content to line up behind other Humira biosims, sues AbbVie over wrongful monopoly - FiercePharmaAlvotech, not content to line up behind other Humira biosims, sues AbbVie over 'wrongful monopoly' - FiercePharma
fiercepharma.com - May 11 at 3:42 PM
AbbVie Enters Growing Market for Tattoo Removal, Cellulite TreatmentAbbVie Enters Growing Market for Tattoo Removal, Cellulite Treatment
gurufocus.com - May 11 at 3:04 PM
SMC Accepts AbbVies RINVOQ® (upadacitinib) For Use in Adults with Active Psoriatic Arthritis - PharmiWeb.comSMC Accepts AbbVie's RINVOQ® (upadacitinib) For Use in Adults with Active Psoriatic Arthritis - PharmiWeb.com
pharmiweb.com - May 11 at 10:42 AM
Alvotech Seeks to End AbbVies Wrongful Monopoly on Humira and Bring Affordable Arthritis Treatment to U.S. - Business WireAlvotech Seeks to End AbbVie's Wrongful Monopoly on Humira and Bring Affordable Arthritis Treatment to U.S. - Business Wire
businesswire.com - May 11 at 10:42 AM
An AbbVie clinical vet heading early oncology jumps ship to build his own team at NK cell-focused biotech - Endpoints NewsAn AbbVie clinical vet heading early oncology jumps ship to build his own team at NK cell-focused biotech - Endpoints News
endpts.com - May 11 at 10:42 AM
AbbVie Subsidiary Scoops Up Soliton and Its Cellulite, Tattoo Removal Device - BioSpaceAbbVie Subsidiary Scoops Up Soliton and Its Cellulite, Tattoo Removal Device - BioSpace
biospace.com - May 11 at 10:42 AM
AbbVie Unit To Acquire Soliton For $550M To Boost Aesthetics UnitAbbVie Unit To Acquire Soliton For $550M To Boost Aesthetics Unit
finance.yahoo.com - May 11 at 10:42 AM
AbbVies Allergan Aesthetics dishes out $550M for Soliton and its cellulite, tattoo remover - FierceBiotechAbbVie's Allergan Aesthetics dishes out $550M for Soliton and its cellulite, tattoo remover - FierceBiotech
fiercebiotech.com - May 10 at 7:42 PM
AbbVie (NYSE:ABBV) Hits New 12-Month High Following Analyst UpgradeAbbVie (NYSE:ABBV) Hits New 12-Month High Following Analyst Upgrade
americanbankingnews.com - May 10 at 12:34 PM
AbbVie (NYSE:ABBV) Price Target Increased to $129.00 by Analysts at BMO Capital MarketsAbbVie (NYSE:ABBV) Price Target Increased to $129.00 by Analysts at BMO Capital Markets
americanbankingnews.com - May 10 at 10:12 AM
Ground broken on new middle school built with AbbVie donation - Daily HeraldGround broken on new middle school built with AbbVie donation - Daily Herald
dailyherald.com - May 8 at 7:26 PM
$2.91 EPS Expected for AbbVie Inc. (NYSE:ABBV) This Quarter$2.91 EPS Expected for AbbVie Inc. (NYSE:ABBV) This Quarter
americanbankingnews.com - May 8 at 6:10 PM
Better Dividend Stock: AbbVie or Pfizer? - Motley FoolBetter Dividend Stock: AbbVie or Pfizer? - Motley Fool
fool.com - May 8 at 2:26 PM
Better Dividend Stock: AbbVie or Pfizer? - NasdaqBetter Dividend Stock: AbbVie or Pfizer? - Nasdaq
nasdaq.com - May 8 at 9:26 AM
Is It Too Late to Buy AbbVie Stock in 2021? - Motley FoolIs It Too Late to Buy AbbVie Stock in 2021? - Motley Fool
fool.com - May 8 at 9:26 AM
AbbVie (NYSE:ABBV) Price Target Raised to $124.00AbbVie (NYSE:ABBV) Price Target Raised to $124.00
marketbeat.com - April 30 at 4:41 PM
AbbVie Remains One of the Best Buys in Its Sector AbbVie Remains One of the Best Buys in Its Sector
marketbeat.com - April 29 at 11:51 AM
3 Healthy Pharmaceutical Stocks to Buy Now3 Healthy Pharmaceutical Stocks to Buy Now
marketbeat.com - April 21 at 8:27 PM
3 High Dividend Large Caps Worth Buying3 High Dividend Large Caps Worth Buying
marketbeat.com - February 10 at 1:43 PM
Get Ready To See AbbVie Stock Back At All Time HighsGet Ready To See AbbVie Stock Back At All Time Highs
marketbeat.com - February 4 at 8:52 AM
AbbVie (NYSE:ABBV) Is a Classic Buy the Dip CandidateAbbVie (NYSE:ABBV) Is a Classic Buy the Dip Candidate
marketbeat.com - February 1 at 11:21 AM
Three High-Yield Dividend Stocks For 2021 And Beyond (ABBV)Three High-Yield Dividend Stocks For 2021 And Beyond (ABBV)
marketbeat.com - December 29 at 8:39 AM
DateCompanyBrokerageAction
5/13/2021PfizerThe Goldman Sachs GroupReiterated Rating
5/12/2021PfizerMizuhoReiterated Rating
5/11/2021PfizerSVB LeerinkBoost Price Target
5/10/2021PfizerMorgan StanleyBoost Price Target
5/5/2021PfizerJPMorgan Chase & Co.Boost Price Target
5/5/2021PfizerBarclaysBoost Price Target
4/7/2021PfizerRoyal Bank of CanadaInitiated Coverage
3/23/2021PfizerBerenberg BankReiterated Rating
2/3/2021PfizerDZ BankReiterated Rating
4/28/2021NovartisOddo BhfUpgrade
4/19/2021NovartisUBS GroupReiterated Rating
3/23/2021NovartisSociete GeneraleReiterated Rating
3/22/2021NovartisSanford C. BernsteinInitiated Coverage
3/16/2021NovartisArgusReiterated Rating
2/1/2021NovartisCowenDowngrade
1/15/2021NovartisDeutsche Bank AktiengesellschaftInitiated Coverage
6/15/2020NovartisCitigroupUpgrade
4/21/2021Abbott LaboratoriesAtlantic SecuritiesInitiated Coverage
4/20/2021Abbott LaboratoriesWilliam BlairReiterated Rating
3/17/2021Abbott LaboratoriesRaymond JamesBoost Price Target
1/28/2021Abbott LaboratoriesWells Fargo & CompanyBoost Price Target
1/28/2021Abbott LaboratoriesCredit Suisse GroupBoost Price Target
1/28/2021Abbott LaboratoriesBTIG ResearchUpgrade
10/22/2020Abbott LaboratoriesJefferies Financial GroupBoost Price Target
9/11/2020Abbott LaboratoriesWolfe ResearchInitiated Coverage
2/5/2021Merck & Co., Inc.Cantor FitzgeraldReiterated Rating
10/23/2020Merck & Co., Inc.TruistInitiated Coverage
4/29/2020Merck & Co., Inc.GuggenheimLower Price Target
5/10/2021AbbVieBMO Capital MarketsBoost Price Target
4/30/2021AbbViePiper SandlerBoost Price Target
(Data available from 5/13/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.